Thiocolchicoside
MUSCULO-SKELETAL SYSTEM
Also known as: coltramyl, muscoril, thiocholshikoside
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Thiocolchicoside is a drug catalogued in DrugCentral. DrugCentral lists 4 molecular targets, including GABRG2|GABRA2|GABRB2, GABRA1|GABRB1|GABRG2 and GABRA1|GABRG2|GABRB2. Recorded indications include Spasticity.
- Molecular targets: GABRG2|GABRA2|GABRB2, GABRA1|GABRB1|GABRG2, GABRA1|GABRG2|GABRB2 and Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre (4 listed in DrugCentral).
- Indications: Spasticity.
- ATC code: M03BX05 (Other centrally acting agents).
- Molecular formula: C27H33NO10S; molecular weight 563.62 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Spasticity
Mechanism & targets
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| GABA A receptor alpha-2/beta-2/gamma-2 | GABRG2|GABRA2|GABRB2 | other | IC50 6.89 |
| GABA A receptor alpha-1/beta-1/gamma-2 | GABRA1|GABRB1|GABRG2 | other | IC50 6.82 |
| GABA-A receptor alpha-1/beta-2/gamma-2 | GABRA1|GABRG2|GABRB2 | other | IC50 6.70 |
| GABA-A receptor; anion channel | Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre | unknown | IC50 5.72 |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
M03BX05 | MUSCULO-SKELETAL SYSTEM › MUSCLE RELAXANTS › MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS › Other centrally acting agents |
M03BX55 | MUSCULO-SKELETAL SYSTEM › MUSCLE RELAXANTS › MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS › Other centrally acting agents |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Hepatocellular injury | 64.0 |
| Poisoning deliberate | 58.7 |
| Palatal oedema | 57.0 |
| Angioedema | 54.8 |
| Melaena | 52.2 |
| Cholestasis | 51.0 |
| Erythema | 43.5 |
| Pancreas infection | 43.5 |
| Panic attack | 42.4 |
| Vitamin B12 deficiency | 41.7 |
| Accidental poisoning | 41.0 |
| Laryngeal dyspnoea | 40.3 |
Chemical structure
| Molecular formula | C27H33NO10S |
|---|---|
| Molecular weight | 563.62 g/mol |
| CAS number | 602-41-5 |
| InChIKey | LEQAKWQJCITZNK-AXHKHJLKSA-N |
| PubChem CID | 9915886 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Thiocolchicoside used for?
DrugCentral lists the following indications for Thiocolchicoside: Spasticity.
How does Thiocolchicoside work?
Its molecular targets in DrugCentral include GABRG2|GABRA2|GABRB2, GABRA1|GABRB1|GABRG2, GABRA1|GABRG2|GABRB2 and Gabrp|Gabrb1|Gabrd|Gabrg2|Gabra5|Gabra3|Gabrg1|Gabra2|Gabra4|Gabrg3|Gabra6|Gabra1|Gabrb3|Gabrb2|Gabrq|Gabre.
What is the chemical formula of Thiocolchicoside?
Thiocolchicoside has the molecular formula C27H33NO10S and a molecular weight of 563.62 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4731 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL213907 — compound record and bioactivity
- PubChem CID 9915886 — chemical identifiers
- DrugBank DB11582 — drug record
- FDA UNII T1X8S697GT — substance identity
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.